文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

孤立性5q缺失骨髓增生异常综合征预后因素的综合分析

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.
PubMed 文献 · Blood Adv · 2026-01-01

该国际队列纳入682例孤立性5q缺失MDS患者,评估IPSS-R与IPSS-M的判别能力并开发疾病特异性工具IPSS-del(5q)。多数患者被IPSS-R(94.4%)和IPSS-M(85.5%)归为较低危,但两系统判别能力有限(C指数约0.5)。IPSS-del(5q)将患者分为标准危(74.3%)和高危(25.7%),无白血病生存期分别为69.2个月与32.0个月(P<.01),但C指数仅0.60。

要点

  • IPSS-R与IPSS-M在MDS-del(5q)中判别能力有限,C指数约0.5。
  • IPSS-del(5q)区分标准危与高危,无白血病生存69.2 vs 32.0个月。
  • 该模型将部分IPSS-R/IPSS-M较低危患者重新归为高危。

核心结论

  • 现有MDS预后评分在MDS-del(5q)中判别能力有限,需开发更精细的疾病特异性预后方法。

研究设计与样本

  • 国际多中心队列研究,纳入682例MDS-del(5q)患者,评估IPSS-R与IPSS-M并开发IPSS-del(5q)。

主要发现

  • IPSS-R将94.4%患者归为较低危,IPSS-M将85.5%归为较低危,两者C指数均约0.5。
  • 独立不良预后因素包括年龄≥70岁、男性、血红蛋白≤10 g/dL、血小板≤100×10^9/L、1个额外染色体异常、≥2个基因突变、SF3B1突变及高危TP53状态。
  • IPSS-del(5q)含6个变量,将患者分为标准危(74.3%)和高危(25.7%),无白血病生存分别为69.2个月与32.0个月(P<.01)。
  • IPSS-del(5q)将19.1%的IPSS-R较低危患者和14.6%的IPSS-M较低危患者重新归为高危,C指数为0.60。

关键数值与推荐

  • IPSS-del(5q)标准危组无白血病生存69.2个月,高危组32.0个月(P<.01)。
  • IPSS-del(5q)的C指数为0.60。

临床怎么用

  • 对MDS-del(5q)患者可考虑用IPSS-del(5q)识别传统评分低估的高危患者。

局限性

  • IPSS-del(5q)判别能力仍有限,C指数仅0.60。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myelodysplastic syndromes (MDS) with isolated deletion of chromosome 5q [MDS-del(5q)] constitute a distinct biological entity traditionally associated with favorable outcomes, although up to one-quarter of patients progress to acute myeloid leukemia (AML). Existing prognostic models, developed in heterogeneous MDS populations, may not adequately capture risk within this subgroup. We assembled an international cohort of 682 patients with MDS-del(5q) to evaluate the performance of the Revised International Prognostic Scoring System (IPSS-R) and its molecular version (IPSS-M), identify prognostic variables, and develop a disease-specific prognostic tool, the IPSS-del(5q). Most patients were classified as lower risk by IPSS-R (94.4%) and IPSS-M (85.5%), yet both systems showed limited discriminatory ability (concordance indices [C-indices] ≈0.5). Independent adverse prognostic factors included age of ≥70 years, male sex, anemia (hemoglobin ≤10 g/dL), thrombocytopenia (platelet count ≤100 × 109/L), the presence of 1 additional chromosomal abnormality, ≥2 gene mutations, SF3B1 mutations, and high-risk TP53 status. Six variables were included in the IPSS-del(5q), stratifying patients into standard-risk (74.3%) and high-risk (25.7%) groups with significantly different leukemia-free survival (69.2 months vs 32.0 months, respectively; P< .01). Moreover, this model reclassified 19.1% of patients in lower-risk IPSS-R group and 14.6% of those in lower-risk IPSS-M group into the high-risk IPSS-del(5q) group. However, its discriminative power remained modest, with a C-index of 0.60. Overall, to our knowledge, this study provides the most comprehensive prognostic evaluation of MDS-del(5q) to date, demonstrates the limited discriminatory capacity of existing MDS scores in this entity, and underscores the need to develop refined disease-specific prognostic approaches for this MDS subtype.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Montoro MJ, Navarro V, Acha P, et al. Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q. Blood Adv. 2026. PMID: 42466989. doi:10.1182/bloodadvances.2026020633

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。